Retrospective observation of subacute thyroiditis before and during the COVID-19 vaccination campaign in a single secondary endocrine centre in the Savona district, Liguria, Italy

Table 1 Clinical and laboratory data collected after COVID-19 vaccination in patients with diagnosis of SAT

Case	Age years	Vaccine type (#)	Weeks after vaccination	Symptoms	f-T4 pmol/l	TSH mIU/l	TPOAb P/N	TRAb mIU/l	CRP mg/l	US findings (*)	Therapy
1	35	mRNA-1273, 2^nd	2	neck pain	12.6	< 0.03	nd	nd	nd	nd	FANs
			6	palpitation	7.6	< 0.03	P	0.5	102	diffuse, 5	none
			14	none	10.6	0.11	P	nd	12	focal, 6	none
2	42	mRNA-1273, 1^st	3	neck pain	26.1	0.01	P	nd	nd	diffuse, nd	FANs
			8	none	nd	4.46	nd	< 0.3	25	normal, 8	none
3	50	BNT162b2, 2^nd	6	neck pain	16.0	0.06	nd	nd	nd	diffuse, nd	FANs
			10	palpitation	20.6	3.03	N	< 0.3	48	normal, 12	none
4	51	ChAdOx1, 1st	4	neck pain	nd	nd	nd	nd	10	diffuse, 20	none
			9	weight gain	5.8	10.4	N	< 0.3	4	diffuse, 5	none
			29	none	12.0	5.30	N	nd	nd	diffuse, 4	L-T4
5	54	BNT162b2, 2^nd	3	neck pain	18.5	0.69	N	nd	nd	diffuse, 13	prednisone
			10	none	11.3	7.60	nd	nd	33	normal, 5	none
6	61	mRNA-1273, 1^st	4	palpitation	15.6	< 0.03	N	nd	nd	focal, 9	B-blocker
			13	none	7.9	0.09	N	0.4	18	normal, 8	B-blocker
7	63	BNT162b2, 1^st	4	neck pain	nd	nd	nd	nd	44	diffuse, 18	prednisone
			12	weight gain	12.4	2.20	N	nd	46	focal, 10	B-blocker

Legend: nd, not done; #, 1^st or 2^nd vaccine administration before onset of SAT; P/N, positive/negative TPOAb titer; US diffuse, focal hypoechoic pattern; (*) the number indicates thyroid volume in milliliters; FANs, non-steroidal anti-inflammatory drugs

ISSN: 1756-6614